Hinge Health, Inc. (NYSE:HNGE) is spotlighted as one of the 11 newly-listed NYSE stocks to consider buying. KeyBanc reduces its price target on HNGE to $55 from $70 but maintains an Overweight rating. Evercore ISI and Canaccord also adjust their price targets, citing strong financial results and guidance exceeding expectations.

On February 10, 2026, Hinge Health reports Q4 revenue of $170.7M, surpassing consensus estimates. Co-Founder and CEO Daniel Perez highlights strong commercial momentum, expanding margins, and solid cash generation. The company focuses on scaling and automating healthcare delivery for musculoskeletal conditions through AI-powered care models and wearable devices.

Although HNGE shows potential for investment, other AI stocks may offer greater upside potential with lower downside risk. For those interested in exploring undervalued AI stocks, a free report on the best short-term AI stock is available. Disclosure: None.

Read more at Yahoo Finance: KeyBanc Reduces its Price Target on Hinge Health, Inc. (HNGE) to $55 and Maintains an Overweight Rating